Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Date:10/22/2008

ongoing study may support the advancement of picoplatin into a Phase 3 clinical trial for HRPC. Our growing body of safety and efficacy data also supports the potential for additional uses of picoplatin as a combination therapy in the treatment of non-small cell lung and ovarian cancers where platinum and taxane combinations are currently used."

About Picoplatin

Picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and is designed to overcome platinum resistance associated with chemotherapy in solid tumors. It is being studied in multiple cancer indications, combinations and formulations. Picoplatin has been evaluated in more than 750 patients and has demonstrated anti-tumor activity in multiple indications with less severe kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy drugs.

In addition to the ongoing Phase 2 clinical trial in HRPC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registration trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. Picoplatin is also being evaluated in a Phase 2 clinical trial in patients with metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information ple
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC Bulletin Board: ... nutrients for plants and animals, located in the,People,s ... Mr. Sam Yu to be the,Company,s new chief ... Yu,replaces Larry Gilmore, who served as the Company,s ...
... 1 /PRNewswire-Asia-FirstCall/ -- Kun Run,Biotechnology, Inc., (OTC Bulletin Board: ... manufacture and sales of peptides and,peptide-based drugs, today announced ... , Revenues for the year ... $4.1 million, or 56% over revenues for the same ...
... ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April ... that,continually defines the client-service standard with its inherently ... CHDX ), today announced a,partnership to provide central ... (UFH). UFH is a CAP-certified facility owned ...
Cached Biology Technology:Yongye Biotechnology Appoints New Chief Financial Officer 2Yongye Biotechnology Appoints New Chief Financial Officer 3Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 2Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 3Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 4Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 5Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 6Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 7Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 8ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 2ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 3ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 4
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... are twice as high among people born in Scotland or ... has shown. Research, conducted by the University of Edinburgh ... born in India but living in England and Wales ... Irish-born people. The findings showed too that people born ...
... research in the ESA journals Frontiers in Ecology and ... and Ecological Monographs . 1. Fuel ... invasives , Ecological Applications ... reduction methods under the U.S. National Fire and Fire Surrogate ...
... LANSING, Mich. Prenatal exposure to an insecticide commonly used ... obesity epidemic in women, according to a new study involving ... who live along and eat fish from Lake Michigan were ... DDT. The study, published as an editor,s choice in this ...
Cached Biology News:Scots and Irish at greater risk of drink-related death, study shows 2Highlights from the March editions of ESA journals 2Highlights from the March editions of ESA journals 3Exposure to insecticide may play role in obesity epidemic among some women 2
... Description: Proteinase K is a ... wide range of applications purified from the fungus ... the carboxyl group of N-substituted hydrophobic aliphatic and ... as a serine protease. Proteinase K is useful ...
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
Biology Products: